Nicholas DeVito, Assistant Professor of Medicine at the Division of Medical Oncology at Duke University, shared a post on LinkedIn:
“The CRUSH Colorectal Cancer 5K is just over a month away! The funds generated from this community – building event go directly towards research proposals, community outreach, and patient support initiatives.
Join our team, the BOT/BALlers, named in honor of our first line immunotherapy trial with Botensilimab/Balstilimab (BOT/BAL) in stage IV colorectal cancer. We have completed enrollment (in half the predicted time!) and look forward to sharing results in the coming months. We hope to see you in March.”
More posts featuring Nicholas DeVito